Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda, sending its ...

Federal vaccine policy changes under RFK Jr. have some concerned health insurance will not cover COVID shots. A bill in NY ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...

SHREVEPORT, La. - The U.S. Department of Health and Human Services has announced $500 million in funding cuts to vaccine ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...